Newsroom / COVID-19 tests

In some territories, which are listed in our website footer, our microsampling devices are supplied for therapeutic or IVD use as referenced in some of our content. Outside of those territories our devices are supplied for research use only (RUO).

Quanterix Publishes Study Paper on High-Sensitivity SARS-CoV-2 Test

by Neoteryx, on April 22,2021

At the end of March 2021, Quanterix Corporation issued a press release announcing that its Simoa® technology had been used in a research study to detect the SARS-CoV-2 virus. According …

Read Story

LGC COVID-19 Antibody Assay Processes up to 40,000 Tests Per Day in UK

by Neoteryx, on September 23,2020

LOS ANGELES and Cambridge, UK — September 2020 — The first commercially available SARS-CoV-2 antibody test in the UK compatible with Neoteryx’s Mitra® Microsampling device for at-home blood collection has …

Read Story

COVID-19 Tests? Consider a Finger-Prick Instead of a Regular Blood Draw

by Neoteryx, on April 29,2020

“COVID-19 testing is top-of-mind for every researcher around the world at present, and effective testing is an important part of every coronavirus pandemic safety plan. Testing can potentially be done …

Read Story

Mitra^® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.

hemaPEN^® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN^® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.

Newsroom / COVID-19 tests

Quanterix Publishes Study Paper on High-Sensitivity SARS-CoV-2 Test

LGC COVID-19 Antibody Assay Processes up to 40,000 Tests Per Day in UK

COVID-19 Tests? Consider a Finger-Prick Instead of a Regular Blood Draw

search our newsroom

news reporter resources:

social media

subscribe to news

Fuel Your Innovative Approach to Science & Research. Subscribe to Our Microsampling Newsletter!

Get in Touch

Neoteryx, LLC

Get To Know Us

Follow Us